Defining the Contribution of ENaC to ADH-mediated Water and Sodium Excretion
定义 ENaC 对 ADH 介导的水和钠排泄的贡献
基本信息
- 批准号:9105117
- 负责人:
- 金额:$ 32.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-25 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdrenalectomyAgonistAldosteroneAnimalsBindingBloodBlood PressureCellsChronicConflict (Psychology)DiseaseDistalDuct (organ) structureElementsEpithelialEquilibriumExcretory functionExtracellular FluidFeedbackGap JunctionsHomeostasisHypertensionHyponatremiaInappropriate ADH SyndromeInfusion proceduresKidneyKnockout MiceKnowledgeLeadLinkLiquid substanceMediatingMedicalMethodologyMovementMusNatureNephronsOsmolalitiesOutcomePathogenesisPathologicPermeabilityPlasmaPlayPositioning AttributePreventionReagentReceptor ActivationReceptor SignalingRegulationRenin-Angiotensin-Aldosterone SystemResearchRoleSerumSignal PathwaySignal TransductionSodiumSodium ChannelSystemSystemic blood pressureTestingThinkingThyroid GlandTubular formationUrineVasopressinsWaterWater MovementsWild Type Mouseabsorptionaquaporin-2blood pressure regulationclinically significantcollecting tubule structuredefined contributiondriving forceepithelial Na+ channelgain of function mutationhormone regulationin vivoinsightkidney interstitial tissuekidney medullamouse modelnovelpatch clamppatient populationpublic health relevancereceptorsolutetreatment strategyubiquitin-protein ligasewater channel
项目摘要
DESCRIPTION (provided by applicant): Antidiuretic hormone (ADH) plays a key role in regulating water balance by controlling renal water transport. ADH binds to the vasopressin-2 receptor (V2R) and increases expression of aquaporin 2 (AQP2) water channels in collecting duct cells to increase renal tubular water permeability. A steep solute corticomedullary gradient in the medullary interstitium provides the driving force for water absorption from tubular fluid in
the distal nephron. We and others have demonstrated that ADH also stimulates activity of the epithelial sodium channel (ENaC) in the collecting duct and that ENaC possibly facilitates urine concentration. However, ENaC is traditionally regarded as the end-effector of the renin-angiotensin-aldosterone system (RAAS) and the final element that controls renal Na+ excretion and thus blood pressure. Yet we have shown that in some cases of hyponatremia, such as after adrenalectomy, ENaC activity is surprisingly robust. After adrenalectomy, serum ADH levels rise, leading to an increase in ADH-mediated ENaC activity. This increase in ENaC activity occurs in the absence of aldosterone, raising many new questions about ADH regulation of ENaC. The notion that ENaC can respond to both ADH and RAAS is at odds with the accepted role of this channel in merely controlling renal Na+ reabsorption and blood pressure. To reconcile the apparent conflicting roles of ADH in regulating both water and balance, we propose a unifying paradigm that defines the contribution of ENaC as a regulator of water and Na+ balance. We hypothesize that simultaneous activation of ENaC and AQP2 by ADH promotes urine concentration and plasma dilution. If parallel signaling pathways stimulate ENaC activity to a sufficiently high level, then ADH-mediated ENaC activation will induce Na+ retention beyond what is needed for urine concentration and lead to hypertension. We will use state-of-the-art methodologies (e.g., patch clamp studies of isolated split-open collecting duct in mice) and novel reagents (connecting segment/collecting duct-specific Nedd4-2 knockout mice) to test three Specific Aims: 1) Test whether ENaC contributes to pathologic renal water reabsorption and hyponatremia, 2) Test whether V2R activation can induce renal Na+ retention and high blood pressure, and 3) Test whether V2R signals through Nedd4-2 to stimulate ENaC in vivo. This proposal will provide mechanistic insights into how ADH, AQP2, and ENaC interact and ultimately control water and Na+ homeostasis. This knowledge is clinically significant because it may suggest new strategies, which are already currently available to clinicians, for the treatment of hyponatremia and hypertension.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN C PAO其他文献
ALAN C PAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN C PAO', 18)}}的其他基金
Defining the Contribution of ENaC to ADH-mediated Water and Sodium Excretion
定义 ENaC 对 ADH 介导的水和钠排泄的贡献
- 批准号:
9319742 - 财政年份:2016
- 资助金额:
$ 32.43万 - 项目类别:
ENaC Regulation by Cell Surface Associated SGK1
细胞表面相关 SGK1 对 ENaC 的调节
- 批准号:
8734591 - 财政年份:2013
- 资助金额:
$ 32.43万 - 项目类别:
Functional Role of the PXL Domain of SGK1 in Epithelial
SGK1 PXL 结构域在上皮细胞中的功能作用
- 批准号:
7023243 - 财政年份:2006
- 资助金额:
$ 32.43万 - 项目类别:
The Functional Role of the PXL Domain of SGK1 in Epithelial Sodium Transport
SGK1 PXL 结构域在上皮钠转运中的功能作用
- 批准号:
7575925 - 财政年份:2006
- 资助金额:
$ 32.43万 - 项目类别:
The Functional Role of the PXL Domain of SGK1 in Epithelial Sodium Transport
SGK1 PXL 结构域在上皮钠转运中的功能作用
- 批准号:
7359681 - 财政年份:2006
- 资助金额:
$ 32.43万 - 项目类别:
The Functional Role of the PXL Domain of SGK1 in Epithelial Sodium Transport
SGK1 PXL 结构域在上皮钠转运中的功能作用
- 批准号:
7786196 - 财政年份:2006
- 资助金额:
$ 32.43万 - 项目类别:
The Functional Role of the PXL Domain of SGK1 in Epithelial Sodium Transport
SGK1 PXL 结构域在上皮钠转运中的功能作用
- 批准号:
7166073 - 财政年份:2006
- 资助金额:
$ 32.43万 - 项目类别:
The Functional Role of the PXL Domain of SGK1 in Epithelial Sodium Transport
SGK1 PXL 结构域在上皮钠转运中的功能作用
- 批准号:
7599686 - 财政年份:2006
- 资助金额:
$ 32.43万 - 项目类别:
Role of SGK2 in Sodium Transport in the Kidney
SGK2 在肾脏钠转运中的作用
- 批准号:
6691521 - 财政年份:2004
- 资助金额:
$ 32.43万 - 项目类别:
Role of SGK2 in Sodium Transport in the Kidney
SGK2 在肾脏钠转运中的作用
- 批准号:
6917822 - 财政年份:2004
- 资助金额:
$ 32.43万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 32.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 32.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




